FDA approves orforglipron GLP-1 pill

The U.S. Food and Drug Administration approved Eli Lilly’s Foundayo, the brand name for orforglipron, on April 1, 2026, for adults with obesity or adults who are overweight and have at least one weight-related condition. The approval covers chronic weight management alongside a reduced-calorie diet and increased physical activity, according to the FDA and Lilly. The tablet is a GLP-1 receptor agonist taken once daily. Its label says it can be taken with or without food. The April 1 decision makes Foundayo one of the FDA’s novel drug approvals for 2026 and the first new molecular entity cleared under the agency’s Commissioner’s National Priority Voucher pilot program, the FDA said. The agency said it issued the decision 50 days after Lilly’s filing and 294 days before the application’s January 20, 2027 PDUFA date. FDA Commissioner Martin Makary said the review showed what the agency could do with “constant communications” and a shortened review process. (fda.gov) ### What exactly did the FDA approve? Foundayo is approved to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, the FDA said. The approval is for use with diet and exercise, not as a stand-alone treatment. The label also says concomitant use with another GLP-1 receptor agonist is not recommended. (fda.gov) The prescribing information lists a step-up dosing schedule starting at 0.8 mg once daily, rising to 2.5 mg after at least 30 days and then to 5.5 mg after another 30 days. The dose can then increase to 9 mg, 14.5 mg or 17.2 mg after at least 30 days at each level, based on response and tolerability. The maximum dose is 17.2 mg once daily. (fda.gov) ### Why is the pill’s dosing label getting attention? The label says patients should take Foundayo orally once daily “with or without food,” and Lilly said the drug can be taken any time of day without food or water restrictions. That distinguishes it from oral semaglutide, which has fasting-related administration requirements. Lilly and the FDA both described Foundayo as a tablet-form GLP-1 receptor agonist. (fda.gov) David Ricks, Lilly’s chief executive, has previously described orforglipron as a product the company expected to manufacture and launch at scale if approved. In April 2025, Lilly said the drug was the first oral small-molecule GLP-1 receptor agonist to successfully complete a Phase 3 trial. (accessdata.fda.gov) ### Which trials supported the approval? Lilly said the approval was supported by the ATTAIN clinical trial program. In ATTAIN-1, announced on August 7, 2025, Lilly said 3,127 adults with obesity, or overweight with a weight-related medical problem and without diabetes, were enrolled. The company said participants on the highest dose who stayed on treatment lost an average of 27.3 pounds, or 12.4%, compared with 2.2 pounds on placebo. (investor.lilly.com) On August 26, 2025, Lilly said ATTAIN-2 evaluated adults with obesity or overweight and type 2 diabetes. The company said all three doses met the primary and key secondary endpoints at 72 weeks, with weight loss, A1C reductions and cardiometabolic improvements versus placebo. (investor.lilly.com) ### What warnings and side effects are on the label? The FDA-approved label carries a boxed warning about the risk of thyroid C-cell tumors. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2, according to the prescribing information. (investor.lilly.com) The label lists the most common adverse reactions, reported in at least 5% of treated patients, as nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence and hair loss. Lilly’s patient materials say gastrointestinal side effects occurred most often when starting treatment or increasing the dose and generally decreased over time. (accessdata.fda.gov) ### When and where will patients be able to get it? Lilly said on April 1 that prescriptions would be accepted immediately through LillyDirect and shipping would begin April 6, followed by broader availability through U.S. retail pharmacies and telehealth providers. A Lilly medical information page says Foundayo is now available through LillyDirect, telehealth providers and U.S. retail pharmacies. (accessdata.fda.gov) Lilly said pricing starts at $25 a month for commercially insured patients and $149 for self-pay through its launch channels. (investor.lilly.com)